DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Okuno SH, Edmonson JH, Mahoney MR, Buckner JC, Frytak S, Galanis E.
Limited activity and acceptable toxicity of gemcitabine in a phase II study of patients with advanced sarcomas: a Mayo Cancer Center study.
Proc Am Soc Clin Oncol 2000; 19: 555a(abstr)
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.